Table 2.

Schedule of evaluations for provider participants.

Measure and definition				Baseline		Week 36 (study exit)					Week 48 (poststudy)
Sociodemographic
		Age, sex, race, ethnicity, type of professional (physician, nurse practitioner, physician assistant), years in practice		xa		—b					—
Informed consent				—		—					—
Improve provider hydroxyurea awareness, prescribing, and monitoring behaviors (Aim 2)
	Self-efficacy and hydroxyurea knowledge
			Perceived confidence in prescribing hydroxyurea to patients with SCDc, including correct daily dosing		x		x					—
Engagement of providers related to the use of the HU Toolbox app (Aim 2a)
	Implementation and mHealth satisfaction
			Perceived usability and acceptability of mHealth intervention (MARSd scale) [64]		—		x					—
	Hydroxyurea prescribing practices (clinic-level measures)
			Total number of patients with SCD		x		x					x
			Number of patients eligible to receive hydroxyurea therapy at provider participant’s sitee		x		x					x
			Number of hydroxyurea-eligible patients who are prescribed hydroxyurea (all sickle genotypes)e		x		x					x
Evaluation of facilitators and barriers to implementation of the mHealth app (Aim 3)
	Barriers and facilitators to implementation
			Qualitative interviewsf		—				x		—

^ax denotes done at this time point.

^bDenotes not done at this time point.

^cSCD: sickle cell disease.

^dMARS: mobile app rating scale.

^eHydroxyurea eligibility will follow the 2014 National Health Lung and Blood Institute guidelines as follows: hydroxyurea should be offered to all children with homozygous sickle hemoglobin mutation (HbSS) and compount heterozygous sickle hemoglobin and null beta thalassemia (HbSβ⁰-thalassemia) age ≥9 months and prescribed to all symptomatic adults with HbSS/HbSβ⁰-thalassemia, that is, >3 episodes of severe vaso-occlusion in the preceding 9 months [13].

^fConducted at the end of the study at each site.